| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | I kappa B kinase 2; I kappa B kinase beta; I-kappa-B kinase 2; I-kappa-B-kinase beta; IkBKB; IKK beta; IKK-B; IKK-beta; IKK2; IKKB; IKKB_HUMAN; IMD15; Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase beta; Inhibitor of nuclear factor kappa-B kinase subunit beta; NFKBIKB; Nuclear factor NF-kappa-B inhibitor kinase beta |
| Antigen | |
| Clonality | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Immunogen | Peptide sequence around aa.197~201 (Q-K-Y-T-V) derived from Human IKK-b. |
| Isotype | |
| Product Type | |
| Reactivity | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Storage | |
| Target | |
| UniProt # |
Product Overview
Primary AntibodyThis antibody targets IKBKB and was raised against a recombinant protein immunogen.
Validated Applications
| Application | Recommended Dilution |
|---|---|
| ELISA | WB:1:500-1:1000, IF:1:100-1:200 |
| Western Blot (WB) | WB:1:500-1:1000, IF:1:100-1:200 |
| Immunofluorescence (IF) | WB:1:500-1:1000, IF:1:100-1:200 |
Antibody Specifications
| Target | IKBKB |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat |
| Purification | Affinity Purification |
| Antigen / Immunogen | Peptide sequence around aa.197~201 (Q-K-Y-T-V) derived from Human IKK-b. |
| Production | This product is a polyclonal antibody purified from rabbit antiserum. |
| Form | Liquid |
| Storage Buffer | PBS, 150mM NaCl, 0.02% sodium azide, 50% glycerol, pH 7.4. |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
Alternative Names
I kappa B kinase 2; I kappa B kinase beta; I-kappa-B kinase 2; I-kappa-B-kinase beta; IkBKB; IKK beta; IKK-B; IKK-beta; IKK2; IKKB; IKKB_HUMAN; IMD15; Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase beta; Inhibitor of nuclear factor kappa-B kinase subunit beta; NFKBIKB; Nuclear factor NF-kappa-B inhibitor kinase beta
Safety & Handling
| Target | IKBKB |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat |
| Purification | Affinity Purification |
| Antigen/Immunogen | Peptide sequence around aa.197~201 (Q-K-Y-T-V) derived from Human IKK-b. |
| Production | This product is a polyclonal antibody purified from rabbit antiserum. |
| Form | Liquid |
| Storage Buffer | PBS, 150mM NaCl, 0.02% sodium azide, 50% glycerol, pH 7.4. |
| Storage | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze. |
Dilutions are starting recommendations. Titration is advised for each system.
| Application | Recommended Dilution |
|---|---|
| ELISA | WB:1:500-1:1000, IF:1:100-1:200 |
| Western Blot (WB) | WB:1:500-1:1000, IF:1:100-1:200 |
| Immunofluorescence (IF) | WB:1:500-1:1000, IF:1:100-1:200 |
Immunogen: Peptide sequence around aa.197~201 (Q-K-Y-T-V) derived from Human IKK-b.
Antigen Species: Human
Alternative Names
I kappa B kinase 2; I kappa B kinase beta; I-kappa-B kinase 2; I-kappa-B-kinase beta; IkBKB; IKK beta; IKK-B; IKK-beta; IKK2; IKKB; IKKB_HUMAN; IMD15; Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase beta; Inhibitor of nuclear factor kappa-B kinase subunit beta; NFKBIKB; Nuclear factor NF-kappa-B inhibitor kinase beta
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
